Bagmatic NOVO is our new blood collection monitor serving the special needs of mobile blood donations. As a light weight device with outstanding long battery life, it is developed to take a ...

Single-bar systems are great for smaller TVs, as their length allows for built-in stereo sound while still being compact. But a soundbar-and-subwoofer combo is better suited for a living room home ...

Ever feel like you missed the boat in buying the most successful stocks? Then you’ll want to hear this. On rare occasions, our expert team of analysts issues a “Double Down” stock ...

Novo Nordisk A/S dominates in diabetes and weight-loss drugs, particularly with semaglutide, making it a strong buy. Record investments in 2024 to enhance supply chain and production capacity ...

Novo Nordisk's profit of DKK28.23 billion also topped estimates. Wegovy sales soared 107% at constant exchange rates to DKK19.87 billion, just below estimates. Ozempic sales rose 12% to DKK33.85 ...

Novo Nordisk A/S today announced 2024 earnings, reporting a 26% increase in annual sales to ~$40.56bn and a 26% rise in operating profit to ~$17.91bn for 2024. The company’s GLP-1 drugs, Ozempic ...

Danish pharmaceutical behemoth Novo Nordisk on Wednesday reported better-than-expected net profit in the fourth quarter, amid soaring demand for its Wegovy obesity drugs. Net profit for the fourth ...

Europe's largest pharmaceutical firm, Novo Nordisk, reported fourth-quarter earnings that surpassed analysts' expectations. The company’s shares jumped more than 6% at the market open in Europe ...

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Novo Nordisk A/S ("Novo" or "the Company") (NYSE:NVO) for violations of 10(b ...

NEW ORLEANS — Roy Markey Jr., owner of Markey’s Bar, remembers exactly where he was when he received his introduction to the Eagles’ fan base. It was Jan. 3, 1993, and Philadelphia was playing New ...

Danish drugmaker Novo Nordisk on Wednesday posted another quarter of rapid profit growth, though the story for once wasn’t its wildly popular weight-loss drugs. Novo Nordisk said its fourth ...

Danish drugmaker Novo Nordisk (NVO) reported fourth quarter and full year 2024 earnings Wednesday, beating Wall Street's expectations and bumping its stock up more than 4% at market open.